No Data
No Data
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Apellis Pharmaceuticals’ (APLS Quick QuoteAPLS - Free Report) marketed portfolio comprises two drugs — Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection).
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $49
Mizuho Securities analyst Graig Suvannavejh maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $52 to $49.According to TipRanks data, the analyst has a
Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $49 From $52
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $82
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
Apellis Pharmaceuticals Price Target Maintained With a $100.00/Share by Baird
Apellis Pharmaceuticals Price Target Maintained With a $100.00/Share by Baird